Avidity Biosciences (RNA) FCF Margin (2019 - 2025)
Historic FCF Margin for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to 1257.6%.
- Avidity Biosciences' FCF Margin rose 16242100.0% to 1257.6% in Q3 2025 from the same period last year, while for Sep 2025 it was 2838.14%, marking a year-over-year decrease of 9748300.0%. This contributed to the annual value of 2825.88% for FY2024, which is 15362100.0% down from last year.
- As of Q3 2025, Avidity Biosciences' FCF Margin stood at 1257.6%, which was up 16242100.0% from 5277.07% recorded in Q2 2025.
- In the past 5 years, Avidity Biosciences' FCF Margin registered a high of 713.09% during Q4 2023, and its lowest value of 8174.32% during Q1 2025.
- For the 5-year period, Avidity Biosciences' FCF Margin averaged around 2202.46%, with its median value being 1689.81% (2022).
- As far as peak fluctuations go, Avidity Biosciences' FCF Margin surged by 21590600bps in 2023, and later plummeted by -61620400bps in 2025.
- Avidity Biosciences' FCF Margin (Quarter) stood at 1507.67% in 2021, then rose by 4bps to 1445.97% in 2022, then soared by 149bps to 713.09% in 2023, then tumbled by -590bps to 3490.99% in 2024, then skyrocketed by 64bps to 1257.6% in 2025.
- Its FCF Margin was 1257.6% in Q3 2025, compared to 5277.07% in Q2 2025 and 8174.32% in Q1 2025.